Search Results

MC# 21-22
A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-Fluorouracil + Leucovorin in advanced pancreatic cancer

MC# 21-28
A Phase I/II Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

MC# 22-21
A Phase I, Open-label, Multi-center, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Have Progressed on at Least Two Prior Systemic Therapies

MC# 22-27
A Phase I, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer

MC# 22-38
A Phase II Study of CTX-009 in Adult Patients with Metastatic Colorectal Cancer who have received Two or Three Prior Systemic Chemotherapy Regimens

MC# 23-17
A Phase I Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer

MC# 20-23
An Open-label, Multicenter Phase I/II Dose Escalation and Expansion Study of THOR 707 as a Single Agent and as a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors

MC# 20-26
Tumor-Agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

MC# 21-04
BETA-PRIME: A Phase I/II, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects with Refractory Solid Tumors

MC# 21-12
An Exploratory Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ON 123300 Capsules Administered Orally as Escalating Daily Doses in Patients with Advanced Cancer Relapsed or Refractory to at Least One (1) Prior Line of Therapy

MC# 21-21
A Phase Ib/II, Open-label, Multi-center Study of ERAS-007 (ERK Inhibitor) Administered as Monotherapy or in Combination with ERAS-601 (SHP2 Inhibitor) to Patients with Advanced or Metastatic Solid Tumors

MC# 21-25
An Open Label, Phase I Dose Escalation Trial, with Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients with Advanced or Metastatic Solid Tumors with HER2 Aberrations

MC# 21-26
A Phase I, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients with Relapsed or Refractory Malignancies

MC# 21-27
A Phase Ia/Ib, Open-label, Multicentre Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of BI 1823911 as a Monotherapy and in Combination with Other Anti-cancer Therapies in Patients with Advanced or Metastatic Solid Tumours Expressing KRAS G12C Mutation

MC# 21-29
A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors

MC# 21-41
A Phase I/II Study of ASP1570 in Participants with Locally Advanced or Metastatic Solid Tumors

MC# 21-42
A Phase I Study of The Safety and Tolerability of COM902 in Subjects with Advanced Malignancies

MC# 22-02
A First-in-human, Phase I/II, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination with PARP Inhibitor Senaparib in Patients with Advanced Solid Tumors

MC# 22-04
A Phase I Study of BAL0891 as Monotherapy and in Combination with Chemotherapy in Patients with Advanced Solid Tumors

MC# 22-12
A Phase I, First in Human, Dose-Escalation Study of UCT-01-097 in Participants with Advanced Solid Tumors

MC# 22-13
A Phase I, First in Human, Dose-Escalation Study of UCT-03-008 in Participants with Advanced Solid Tumors

MC# 22-20
An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors

MC# 22-23
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

MC# 22-29
A Phase I, Open-Label, Dose Escalation and Expansion Study of PF-07265028 as a Single Agent and in Combination with Sasanlimab Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PF-07265028 in Participants with Advanced or Metastatic Solid Tumors

MC# 23-02
A First-in-Human, Open-Label, Multi-Center Phase I Study of TST003 in Subjects with Locally Advanced or Metastatic Solid Tumors